About us

Boost Beyond Boundaries

Company History

With years of clinical experience, Astrogen is exploring new horizons
in medications development field at an unprecedented speed.

  • JanuaryReceived the investment of Series C (KRW 12.5 billion)
  • 11월Started of Medical Chemistry Research Institute(Dongtan)
  • 10월Certified as INNO-BIZ
  • 08월ISO 9001 certification
  • ISO 14001 certification
  • ISO 45001 certification
  • JulySelected as ”Baby Unicorn Plus” company by the Ministry of SMEs and Startups
  • Signed an MOU with NEXPHARM
  • Signed an MOU with Johns PHAROS
  • MaySigned an MOU with Neudive
  • Signed an MOU with Johns Hopkins Hospital
  • AprilSigned an MOU with AGATHONBIO
  • FebruarySigned an MOU with Daegu fatima hospital
  • SeptemberSigned an MOU with the Dept. of Neurosurgery
    of Seoul National University Bundang Hospital
  • Signed an MOU with the Molecular Biology &
    Phylogeny Lab. (MPL) of the Dept. of Biological
    Sciences of Pusan National University
  • AugustSelected as Employment-Friendly Company by Daegu City
  • Selected as one of BIG3 projects by the Ministry
    of SMEs and Startups
  • Designated as Startup Growth Technology
    Development Project
  • Received the investment of Bridge 2 (KRW 3 billion)
  • JuneSigned an MOU with the Value Development
    and Play Center
  • MayCompleted observation for the final subject of
    the phase 2 clinical trial for AST-001
  • FebruaryReceived the investment of Bridge 1 (KRW 9 billion)
  • DecemberReceived Presidential Citation for Venture
    Startup Promotion Merit Award
  • Certified as Family-Friendly Company by
    the Ministry of Gender Equality & Family
  • Collaborated with IKTOS, AI-based
    new drug development company
  • NovemberDesignated as Excellent Corporate R&D Center
    by the Ministry of Science and ICT
  • OctoberIntroduced Astrogen’s ESG ethical management
  • SeptemberUploaded the Astrogen ESG Report on the website
  • Selected as Pre-Star Company by Daegu City
  • FebruaryPhase 1 Clinical Study Report for AST-001 (CSR)
  • Enrolled the first trial subject in the phase
    2 clinical trial for AST-001
  • DecemberReceived the investment of Series B (KRW 13 billion)
  • Received Grand Prize at the Daegu Startup Awards
    by the Daegu Center for Creative Economy Innovation
  • Received Minister Award from the Ministry of Trade,
    Industry and Energy for revitalizing free economic zone
  • NovemberSelected as the National Representative Innovative
    Company by the Financial Services Commission
  • AugustOpened the Astrogen's Pharmaceutical Research
    Institute (Naju) Office
  • JulyReceived approval of IND application for phase 2
    clinical trial for AST-001
  • JuneSelected as “Baby Unicorn” company by the Ministry
    of SMEs and Startups
  • MayCompleted construction of Astrogen’s new office building
  • MarchReceived IND for phase 1 clinical trial for AST-001
  • DecemberStarted construction of Astrogen’s new building
    and research center
  • NovemberSelected as the Frontier Venture Company by
    the Korea Technology Finance Corp. (KIBO)
  • Selected as A+ Member by the KIBO
  • AugustReceived the investment of Series A
    (KRW 5 billion of capital increase)
  • MayObtained the approval to move into
    the Daegu-Gyeongbuk Medical Cluster
  • MarchOpened the Astrogen's Business Development
    Division (Seoul) office
  • AugustPre-Series A SEED (KRW 1.9 billion of capital increase)
  • JanuaryObtained the approval for Astrogen Research Center
  • JulyFounded Astrogen, Inc.
  • Obtained Venture Company certification